Technology offer : Vaccine against pregnancy-associated malaria

Technology's description

The World Health Organization estimates that malaria is responsible for 225 millions of cases of infections and approximately one million deaths annually.

Pregnant women are particularly vulnerable because Plasmodium falciparum Infected Erythrocytes (IE) selectively accumulates on the placenta. This placental sequestration of IE severely increases risks of miscarriage, maternal anemia, low birth weight, congenital transmission and neonatal death. A member of the P.falciparum Erythrocyte Membrane Protein 1 (PfEMP1) named VAR2CSA has been identified as the major parasite ligand, and chondroitin sulfate A (CSA) is the major placental receptor for adhesion of IE in the placenta. It is clearly recognized that VAR2CSA is the main target of the acquired protective immunity to placental malaria and therefore an ideal candidate for the development of a vaccine against this clinical form of malaria. The research team selected the best immunogenic regions of the peptides, and developed an antigenic combination using peptides from two P.falciparum lineages. This combination inhibits 100% adhesions of the IE to the CSA making it the best current vaccine candidate for placental malaria.



Advantages

  • No current malaria treatment for pregnant woman
  • Better protection than other vaccine candidate
  • Could be use to protect all young woman at risk
  • Network available for clinical studies
Ref : OT-00015

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Vaccine development

Intellectual property

  • Protected by two patents

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27